Objective: The aim of this study was to investigate the costeffectiveness of osimertinib for the treatment of advanced NSCLC with an EGFR T790M mutation after the failure of first-line EGFR tyrosine kinase inhibitor (TKI) therapy.
Introduction
The Global Burden of Disease 2015 Study revealed that lung cancer is the leading cause of noncommunicable disease burden. 1 Because of its poor outcomes, lung cancer was the most frequent cause of cancer death among all cases globally and among all sociodemographic index quintiles, except in regions with a low sociodemographic index group. 2 The disability-adjusted life-years associated with tracheal, bronchus, and lung cancer were 36.4 million in 2015, of which premature mortality accounted for 99% and years lived with disability accounted for 1%. Approximately 85% to 90% of lung cancers are NSCLC, and 10% to 15% of white patients and 30% to 50% of Asian patients carry EGFR mutations that play a key role in carcinogenesis. First-and second-generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and afatinib have been recommended for the first-line of treatment of advanced EGFR mutation-positive NSCLC because of their significant superiority over standard chemotherapy in prolonging survival. 3 However, resistance against EGFR TKIs develops in patients, with a median progression-free survival (PFS) of 9 to 13 months and with 50% to 60% contributing to the emergence of an EGFR T790M gatekeeper mutation. 4 Osimertinib is a third-generation EGFR TKI designed to inhibit the growth of EGFR T790M-positive tumors; it has been approved for the treatment of patients with advanced NSCLC with EGFR T790M mutations in the United States and numerous other countries. 4 According to the pivotal phase III AURA3 trial, osimertinib treatment significantly prolonged PFS compared with platinum-pemetrexed therapy in patients with T790M-positive advanced NSCLC who experienced disease progression after EGFR TKI therapy ( The clinical benefits of osimertinib treatment in patients for whom first-line EGFR TKI therapy has failed has inspired many oncologists and patients. However, because of the widespread use of osimertinib, the considerable increase in financial burden has become a topic of concern for decision makers in developed and developing regions because patients treated with TKIs are managed until disease progression or absence of tolerability. Economic evaluation of osimertinib has become an urgent need. To the best of our knowledge, the cost-effectiveness of osimertinib has not been assessed. The current analysis investigates the costeffectiveness of osimertinib treatments in patients with advanced NSCLC and disease progression after first-line EGFR TKI therapy in the context of the United States and the People's Republic of China, which represent developed and developing countries, respectively.
Methods

Overview
A mathematical model was established by combining a decision tree and the Markov approach to measure the clinical and economic outcomes of osimertinib treatment in patients with EGFR T790M-positive advanced NSCLC after the failure of first-line therapy with first-generation EGFR TKIs. Because of the considerable impact of health resource consumption associated with mutation testing, the decision trees included the following three scenarios: (1) all patients undergo a blood sample screening to test the T790M mutation in plasma, and those with negative reports in plasma testing undergo a tissue biopsy to examine the T790M mutation status in their tissue; (2) all patients receive only T790M mutation testing in plasma and no further tissue testing for those with negative results in plasma; and (3) only patients with confirmed T790M mutation-positive NSCLC are included. Patients were considered to start either four-cycle pemetrexed plus cisplatin (PC) chemotherapy followed by pemetrexed maintenance therapy or osimertinib treatment after the T790M mutation-positive status was confirmed. A Markov model was established to reflect the disease course of advanced NSCLC, which included the following health states: PFS, progressed survival, and death. The Markov cycle length was 21 days, which is consistent with the schedule of PC chemotherapy, 5 and the time horizon was 10 years. During each Markov cycle, the model redistributes the hypothetical patients among the three health states according to the transition probabilities. The initial state is assumed to be progression-free, and death is the terminal state.
The following outcomes were examined: progressionfree life-years (LYs), overall LYs, quality-adjusted lifeyears (QALYs) and cost. Cost and QALYs were discounted by 3% and 5% annually in the U.S. and Chinese contexts, respectively. The costs are shown as U.S. dollars. All costs have been adjusted to 2017 prices according to the local Consumer Price Index and are shown as US dollars (1 US dollar ¼ 6.8 Chinese yuan renminbi). The incremental cost-effectiveness ratios (ICERs), which are presented as the cost per additional QALY gained, were also examined. As in previous analyses, [6] [7] [8] we used $100,000 and three times the per capita gross domestic product in the People's Republic of China in 2016 ($23,815) as the cost-effectiveness threshold in the U.S. and Chinese contexts, respectively. This economic analysis was based on a literature review and an experimental model and did not require approval from an institutional review board or ethics committee.
Clinical Data
The clinical effectiveness data were obtained from the AURA3 trial. 5 On the basis of the goodness-of-fit examination measured by the R 2 statistic, the Weibull model S(t) ¼ exp(-at b ) and log-logistic survival function
) were used to fit the Kaplan-Meier PFS probabilities of the chemotherapy and osimertinib strategies, 9 respectively. The estimated Weibull and loglogistic model parameters are depicted in Table 1 . 5, [10] [11] [12] [13] [14] [15] After their disease progressed, 24% of the patients received a third line of active chemotherapy according to a recently published systematic review, 12 which included nine studies reporting detailed information regarding real-world treatment patterns in patients who received third-line therapy. The overall survival (OS) rates after disease progression in supportive care and chemotherapy were derived from systematic reviews 10 and fit by the Weibull model. In patients with CNS metastases, the median survival time in supportive care after disease progression was 2.9 months in a retrospective study that analyzed the patterns of events requiring palliative procedures and their impact on the clinical course. 11 The OS rate of patients with CNS metastases receiving chemotherapy was estimated according to the HR of OS in patients with advanced NSCLC who were receiving chemotherapy versus supportive care, which was 0.77 (95% CI: 0.71-0.83) according to the systematic reviews. 10 The frequency of the EGFR T790M mutation was 56.4% (range 28.4%-79.0%) in patients with advanced NSCLC with disease progression after first-line EGFR TKI therapy. 13 To maintain consistency with the trial, the cobas EGFR Mutation Test (Roche Molecular Diagnostics, Pleasanton, CA) was assumed to be used for detecting the T790M mutation, 16 and the specificity and sensitivity of this test were 59.4% and 98.4%, respectively. [13] [14] [15] The specificities and sensitivities of other testing techniques were used in the sensitivity analysis. 13 As shown in Figure 1 , in scenario 1, patients could undergo biopsy for tissue testing if their plasma testing results were negative. The rate of successful rebiopsy was 76.2% (range 63%-86%). [17] [18] [19] The drug adverse event probabilities for each treatment were obtained from the AURA3 trial. 5 We included grade 3 or higher adverse effects because of their considerable impact on the quality of life and health resource utilization.
Cost and Quality of Life Estimates
The cost data were estimated from the perspectives of the payer and the health care systems in the United States and the People's Republic of China. A literature review was performed to determine the cost associated with NSCLC in the United States. The cost estimates used in the analysis are shown in Table 2 . 6, 8, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Osimertinib could be orally administered at a dose of 80 mg once daily until disease progression, and the price was derived from Red Book Online 2016 (Truven Health Analytics, New York, NY) and discounted by 17% to account for contract pricing. 29 The cost of pemetrexedbased chemotherapy and maintenance therapy per cycle was derived from a previous economic evaluation reported by Handorf et al. 6 The duration of PC chemotherapy was assumed to be four cycles in the base-case analysis, and the pemetrexed maintenance therapy could be continued until disease progression. The costs related to adverse events were calculated by multiplying the incidence of the serious adverse events by the costs of managing the serious adverse events per event. 29, 30 [13] [14] [15] PFS, progression-free survival; CNS, central nervous system; OS, overall survival; HR, hazard ratio; SAE, serious adverse event (grade 3).
For patients in the stable disease treatment group receiving salvage chemotherapy and supportive care, the health care resource utilization was estimated according to the reported results. 22 The cost of terminal care during the final 30 days of life was extracted from two recent economic evaluations. 23, 24 Finally, the costs of mutation testing and biopsy were also included. 25 The cost of chemotherapy in the People's Republic of China was derived from a retrospective study involving 384 patients with advanced NSCLC that evaluated costs from 2007 to 2012. 20 Because of the generic competitions and the recent Chinese health care reform of drug prices, a 50% reduction in anticancer drug costs was adjusted according to the current local drug prices. 31 Other costs of managing advanced NSCLC were adopted from our previously published economic evaluations. 8 The costs of osimertinib and EGFR mutation testing were obtained from local hospitals.
Health utility values for each health stage were adopted from a recently published international study that assessed utilities for advanced NSCLC and complications associated with treatment in the United Kingdom, Australia, France, People's Republic of China, Republic of China, and Republic of Korea using a time trade-off technique. 27 The impacts of the following grade III/IV toxicities were considered: diarrhea, fatigue, febrile neutropenia, hair loss, nausea and/or vomiting, neutropenia, and rash. The utility values from another report were used for the sensitivity analysis. 28 
Sensitivity Analyses
To accommodate the uncertainty of the model inputs and test the robustness of the model output, a probabilistic sensitivity analysis and one-way sensitivity analyses were conducted. In the probabilistic sensitivity analysis, 10,000 Monte Carlo simulations were performed by inputting values drawn from their statistical distributions (gamma distribution for costs; normal distribution for log relative risks and health resource utilization; and beta distribution for utilities, probabilities and proportions). A cost-effectiveness curve representing the uncertainty in the model was plotted to show the probability of the cost-effectiveness simulations at various willingness-to-pay thresholds. One-way sensitivity analyses were performed to test the corresponding ICERs by varying each input parameter over a plausible range, as shown in Tables 1 and 2 , which were mainly obtained from reported 95% credible intervals or by a The ranges of osimertinib were assumed for one-way sensitivity analysis. In the United States, the price of osimertinib would be discounted at 17% to account for contract pricing. 29 In the People's Republic of China, patients would receive donated osimertinib from the producer; the patient would pay for 4 months, followed by donations for 8 months in the first year, and would then pay for 3 months, followed by donations until disease progression or death. PC, pemetrexed plus cisplatin; SAE: serious adverse event (grade 3); PFS, progression-free survival; PS, progressed survival. assuming 0.25 or 0.5 times the base-case estimate. The R software package (version 3.3.2; R Development Core Team, Vienna, Austria) was used for the analysis.
Results
Base-Case Analysis
For all patients with an unknown T790M mutation status, the use of EGFR T790M mutation testing in plasma and tissue (scenario 1) and targeted osimertinib treatment in the United States and the People's Republic of China provided an additional 0.359 and 0.327 QALYs, respectively, with incremental $83,515 and $15,730 costs, respectively, compared with standard chemotherapy (Table 3) , which yielded an ICER of $232,895 and $48,081, respectively. In scenario 2 (screening only for T790M mutations in plasma) and scenario 3 (T790M mutation is known, and no mutation testing is performed), the ICERs of osimertinib over chemotherapy were $226,528 and $222,030, respectively, in the United States and $44,806 and $30,472, respectively, in the People's Republic of China.
In the subgroup with CNS metastases in the United States, compared with chemotherapy, the osimertinib treatment in scenarios 1, 2, and 3 provided an additional 0.313, 0.204, and 0.614 QALYs, respectively, with incremental costs of $74,924, $47,216, and $139,355, respectively, which led to ICERs of $239,274, $231,988, and $226,821, respectively. In the Chinese patients with NSCLC with CNS metastases, the ICERs of osimertinib over chemotherapy in scenarios 1, 2, and 3 were $53,244, $49,514 and $33,197, respectively.
Sensitivity Analysis
The results of the one-way sensitivity analyses are shown with tornado diagrams (Fig. 2) . In the comparison of the osimertinib (scenario 1) and chemotherapy in all patients, the model outcome was sensitive to the cost of osimertinib in the United States and the People's Republic of China. The ICER could be lower than the threshold in the United States ($100,000) and the People's Republic of China ($23,815) if the daily cost of osimertinib were reduced by 50%. Other variables, such as the utility values, cost of EGFR mutation testing, and costs associated with managing patients with progressed disease, had a moderate or mild impact on the economic outcomes. However, none of the variables could reduce the ICERs below the thresholds.
The cost-effectiveness curves are shown in Figure 3 . Regardless of the scenarios, the osimertinib strategy was cost-effective in approximately less than 1% of the simulations compared with chemotherapy, considering a cost-effectiveness threshold of $100,000 in the United States and $23,815 in the People's Republic of China.
Discussion
This study is the first to examine the costeffectiveness of osimertinib treatment in patients with first-line EGFR TKI therapy failure as recommended by the latest clinical guidelines, 3 and our results are of great significance in both developed and developing settings. Osimertinib treatment could yield more positive health outcomes in patients with advanced NSCLC with an acquired EGFR T790M mutation than chemotherapy. However, this health benefit is associated with a substantial augmentation of cost, leading to average ICERs higher than $200,000 per QALY in the United States and higher than $30,000 per QALY in the People's Republic of China with or without EGFR mutation testing. For a threshold value of $100,000 and $23,815 per QALY gained in the United States and the People's Republic of China, the osimertinib strategy was not a cost-effective therapeutic approach in either the United States or the People's Republic of China. The acceptability curve also supported this finding, which showed a paucity of certainty that osimertinib was the preferred option at a willingness-to-pay threshold of $100,000 and $23,815 per QALY. Nearly 25% to 40% of patients with NSCLC experience CNS metastases. Because of the impenetrable nature of the blood-brain barrier, the management of CNS metastases continues to be a major challenge. 32 The ability of osimertinib to prevent disease progression was a major determinant of the clinical benefits in subgroup patients with CNS metastases and acquired EGFR T790M mutations. Compared with chemotherapy, osimertinib treatment gained incremental 0.614 and 0.564 QALYs in the United States and China, respectively, with a confirmed EGFR T790M mutation status, which was similar to that in the population including all patients with confirmed EGFR T790M mutations. However, because of its high incremental cost, osimertinib was not considered a cost-effective option in the United States or the People's Republic of China.
The unfavorable ICERs of osimertinib versus chemotherapy were derived principally from the higher acquisition costs of osimertinib. The cost of osimertinib was the most influential factor in the economic outcomes according to the one-way sensitivity analysis. After the price of osimertinib was discounted by 50% of the local price in the United States and the People's Republic of China, osimertinib treatment became a cost-effective alternative to chemotherapy. Because none of the other parameters showed a potential to reduce the ICERs below the threshold, reducing the price of osimertinib might be the most attainable approach for achieving favorable economic outcomes. Notably, the present price of osimertinib in the United States is nearly two times that in the People's Republic of China, which suggests that there is a possibility to decrease the price.
Precision medicine based on genomic testing is an efficient way to select the appropriate regimen for targeted patients, which might improve the health outcomes of the patients using the targeted treatment strategies. However, the introduction of genomic testing may in turn increase health resource utilization. In the current analysis, we also evaluated the impact of a different mutation testing regimen on outcomes of osimertinib for patients whose EGFR T790M mutation status is unknown and who are receiving a different mutation testing regimen. We found that osimertinib treatment with further T790M mutation testing using tissue in those with a negative plasma result (scenario 1) gained more health outcomes by identification of an additional approximately 17.8% patients with T790M mutation and yielded unfavorable ICERs by increasing the costs in comparison with only mutation testing in plasma without further testing using tissue (scenario 2).
When the scenario of no costs related to mutation testing was considered in a subpopulation with confirmed T790M mutation status (scenario 3), the ICERs of osimertinib versus chemotherapy were more favorable than those in scenarios 1 and 2. The one-way sensitivity analysis showed that the higher cost of the EGFR mutation testing may lead to unfavorable economic outcomes; however, the model output was insensitive to this parameter. Recent techniques, such as droplet digital polymerase chain reaction and next-generation sequencing, have been developed but always have a higher cost with a varied sensitivity and specificity in detecting EGFR mutations in plasma. 13 Because these parameters may artificially affect the model output, their economic outcome should be investigated when they are prescribed.
Nevertheless, our study should be interpreted with caution because of several limitations. First, modeling with Weibull and log-logistic functions to extrapolate the long-term PFS beyond the follow-up duration of the trial is an inevitable limitation of this study. However, thanks to the good fitness of the model and the lack of an effect on the PFS in the sensitivity analyses, the model uncertainty surrounding the long-term survival rates is small. Second, this trial-based model did not fully simulate the natural course of the disease in the real-world. These findings may not adequately reflect the efficacy and resource utilization in routine clinical practice, although the sensitivity analysis indicated that the results of this evaluation were robust. Third, the current analysis did not evaluate other new EGFR mutation testing approaches and potential treatments (such as nextgeneration sequencing and immunotherapy) because of the absence of robust head-to-head trial data. Fourth, we did not estimate the budget impact of osimertinib treatment on society. Because of the high global annual incidence of lung cancer, 2 widely prescribing osimertinib could intensively increase health expenditures. Fifth, because of the absence of head-to-head data, the present study did not fully examine other potentially competing alternatives for advanced NSCLC, such as afatinib and immune checkpoint inhibitors, which had shown potentialities of cost-effectiveness. 33, 34 Finally, grades 1 and 2 adverse events were not considered in the analysis, which might underestimate the benefits of osimertinib. However, because the findings of this evaluation reflected the general clinical conditions of managing advanced NSCLC after progression of first-line EGFR TKI therapy, this study might be a valuable reference for decision makers.
In conclusion, from the perspectives of the United States and the People's Republic of China, osimertinib treatment is unlikely to be considered cost-effective in patients with advanced NSCLC and acquired EGFR T790M mutations; however, if the price is reduced, osimertinib may be a cost-effective treatment option. Although the results were reported in the settings of the United States and the People's Republic of China, we are confident that these findings could be easily generalized to other regions because the United States and the People's Republic of China represent developed and developing regions, respectively.
